Aim: In this study, we analyzed the risk of developing pre-eclampsia with respect to glutathione S-transferase theta 1 (GSTT1) and glutathione S-transferase mu 1 (GSTM1) genotypes. We also tried to find relationship between genotypes and biochemical parameter change in pre-eclampsia patients. Methods: In total, 104 pre-eclampsia patients and 200 healthy controls were recruited for the study. Peripheral venous blood was drawn from study subjects and DNA was extracted from whole blood and multiplex polymerase chain reaction method was used to identify genotypes of GSTT1 and GSTM1 gene. All biochemical parameters were measured using colorimetric method. Results: Serum glutamic pyruvic transaminase level was significantly higher (P < 0.01) and hemoglobin level was significantly lower (P < 0.001) in pre-eclampsia patients compared to control subjects. Significant association was found in GSTM1 null genotype with pre-eclampsia (P < 0.001) with an odds ratio (OR) analysis showing more than four-fold increased risk (OR = 4.75; 95% CI = 2.17-10.39; P <0.001). But for GSTT1 gene, null genotype was not associated with increased risk of developing pre-eclampsia (P > 0.05). In case of GSTT1 and GSTM1, the patients having both null genotypes for GSTT1 and GSTM1 showed significant (P < 0.001) higher risk of developing pre-eclampsia (OR = 7.64; 95% CI = 2.38-24.60; P < 0.001). Conclusion: GSTM1 null genotype increases the risk of pre-eclampsia. Combined GSTT1 and GSTM1 null genotype, the risk was even higher.
Introduction
Hypertension in pregnancy or pre-eclampsia is a complication developed in pregnant mother, which is characterized by high blood pressure with complication in another organ system. Women in developing countries are seven times more likely to develop preeclampsia during pregnancy than developed countries. 1 In developing countries, the prevalence rate of pre-eclampsia ranges from 1.8% to 16.7%. 2 Half a million women dies of pregnancy-related complications over the world each year and 99% of the cases occur in developing countries. 3 Study conducted by Khan et al. 4 reported that about 3.4% of the pregnant women were suffering from pre-eclampsia in Bangladesh. Among the patients, 6% died of intrauterine death, 6% undergo abortion and 52% give birth to a premature baby. So this is a major problem for Bangladesh from the perspective of maternal and neonatal mortality. Pre-eclampsia is a multifactorial complication related to pregnancy. More than 70 candidate genes have been studied from different pathways including vasoactive proteins, thrombophilia and hypofibrinolysis, oxidative stress and lipid metabolism, endothelial injury and immunogenetics. 5 Oxidative stress plays a key role in the pathogenesis of pre-eclampsia. At the end of the first trimester, maternal perfusion through placenta starts and oxygen tension increase rapidly. The stability of oxygen tension is acquired by increased expression and activity of antioxidants such as glutathione peroxidase, catalase and the various forms of superoxide dismutase. 6 If antioxidant level or activity decreased, then the cascade events may lead to impaired placenta formation. Different biochemical parameters also vary from the normal value. Serum creatinine to protein ratio increases in preeclamptic patients. 7 Another study showed that aspartate aminotransferase, alanine aminotransferase (ALT), lactate dehydrogenase and total cholesterol differ significantly in pre-eclamptic patients compared to the control group. 8 A study on the Canadian population showed that uric acid level was significantly higher in pre-eclamptic patients compared to hypertensive patients who did not enter into pre-eclamptic condition. 9 Glutathione S-transferase (GST) is an important phase 2 detoxifying enzyme for mammals. It conjugates reduced glutathione (GSH) with toxic xenobiotics and peroxides and thus reduces the oxidative stress of the cell. 10, 11 There are total nine classes of GST. Two of them are glutathione S-transferase theta 1 (GSTT1) and glutathione S-transferase mu 1 (GSTM1). GSTT1 (a cytoplasmic enzyme) has both peroxidase and transferase activity and can be able to detoxify peroxides and thus play a role in peroxidemediated oxidative stress.
12 GSTT1 is absent in 38% of the population and it is important for the detoxification of halomethanes and other industrial chemicals. 13 Similarly, GSTM1 is a cytosolic enzyme which is also important for the detoxification of nitrogen compound and xenobiotic catabolic process.
14 Null allele for both GSTT1 and GSTM1 gene leads to complete loss of enzyme activity. So null allele for both of this gene may lead to decreased peroxide detoxification in different tissue. The study conducted by Yildirim et al. 15 showed that glutathione peroxidase is lower in pre-eclampsia relative to normal pregnancy. Different studies gave contradictory results about GSH level during pre-eclampsia. Study on Turkish population reported lower level of plasma GSH in pre-eclampsia. 16 On the other hand, higher level of GSH found in placental sample in South African women having pre-eclampsia. 17 Genetic polymorphism of various GSH genes and their role in preeclampsia is still in controversy. A study on Turkish population found no relationship between GSH genes polymorphism and pre-eclampsia. 18 Study conducted by Guan et al. 19 found significant relationship between GSTT1 null genotype with pre-eclampsia in the Chinese population. Another study on Mexican population showed higher risk of developing preeclampsia in patients having GSTT1 null genotype and even higher risk for GSTT1 and GSTM1 combined null genotype. 20 Another study on Iranian population revealed that there was no association of GSTT1 and GSTM1 gene polymorphism with preeclampsia. 21 According to the study of Matos et al.,
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GSTT1 null genotype is significantly associated with pre-eclampsia in Portugal.
In our present study, we determined the GSTT1 and GSTM1 null polymorphism in the study population and analyzed their impact on developing preeclampsia in pregnant women of Bangladesh.
Methods Subjects
Totally, 304 unrelated Bangladeshi subjects were selected for the study. Among them, 104 are preeclampsia patients. The pre-eclampsia patients were recruited from Dhaka medical college hospital without any history of other chronic diseases. Patients having increased blood pressure (>140/90) was observed during the last week of the second trimester. The blood sample was taken in the first week of the third trimester from the patients having an increased blood pressure in two measurements at least 4 h apart and ≥1
+ on dipstick urinalysis in two samples taken ≥6 h apart. 9 Totally, 200 pregnant women with no history of pre-eclampsia and other chronic diseases were recruited as controls from different hospitals of Dhaka city while they came for a regular checkup. Blood samples were taken from control subjects at the first week of the third trimester similar to the patients. All participants were given an explanation of the nature of the study and informed consent was obtained. They completed a structured questionnaire covering information on age, number of pregnancy, family planning method, history of pre-eclampsia, physical complications (hypertension, diabetes mellitus, renal problem, leg swelling, headache, vision blurring and vomiting), and biochemical parameters (hemoglobin, serum creatinine, uric acid, serum ALT or serum glutamic pyruvic transaminase [SGPT] and random blood sugar [RBS] ). There was no significant difference in baseline characteristics between controls and cases except SGPT and hemoglobin ( Table 1) . The study was approved by the departmental ethical committee. The study was conducted in accordance with the declaration of Helsinki and its subsequent revisions. 23 
Sample collection
Approximately 3.0 mL of venous blood was drawn from each individual following all aseptic precautions with the help of a trained person, using a disposable syringe. The drawn blood was immediately transferred to a tube containing ethylenediaminetetraacetic acid (1.20 mg/mL). All tubes kept in an ice box for transportation to the laboratory. The whole blood samples were stored at −20 C until DNA extraction.
GSTM1 and GSTT1 genotyping
DNA was extracted from peripheral leukocyte according to the method of Bailes et al. 24 GSTM1 and GSTT1 genotyping was done using multiplex polymerase chain reaction (PCR) method. 25 GSTM1, GSTT1 and Cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1) fragments were amplified by using the primers described earlier. 25 A part of exon −7 CYP1A1 was amplified as an internal control to ensure that a null genotype was due to the absence of GSTM1 and GSTT1 alleles rather than failure of PCR in this method. Negative controls also used for all amplifications.
A volume of 10 μL of the co-amplified products (GSTM1: 215 bp; GSTT1: 466 bp and exon -7 CYP1A1: 312 bp) were analyzed by electrophoresis on 2% agarose gel. After electrophoresis, the gel was stained with ethidium bromide and visualized under ultraviolet (UV) light in a UV transilluminator (Fig. 1) . The presence of a 215 bp band indicated that this subject was homozygote or heterozygote for GSTM1 gene polymorphism, while its absence in the presence of internal control band of CYP1A1 indicated the null GSTM1 genotype. The presence of a 466 bp band indicated that the subject was heterozygote or homozygote for GSTT1 gene polymorphism, while its absence in the presence of CYP1A1 control band indicated the null GSTT1 genotype.
Statistical analysis
Statistical analyses were performed using SPSS, Windows, version 24. The relative association between cases and controls was assessed by calculating the odds ratio (OR). OR, as a measure of relative risk, at 95% confidence intervals (95% confidence interval [CI]) were estimated using logistic regression models. t-Test and chi-square test were performed using GraphPad Prism, version-7. P value less than 0.05 was considered as statistically significant.
Results
In this study, we examined the association of GSTM1 and GSTT1 gene polymorphism as a risk factor for developing pre-eclampsia during pregnancy. According to Table 1 , SGPT level was significantly higher in pre-eclampsia patients compared to control group (P < 0.01). In addition, hemoglobin level was significantly lower in patient group when compared to control group (P < 0.001). Other parameters such as age, RBS, uric acid and creatinine showed no significance between two groups. Genotypic distribution and analysis of GSTM1 and GSTT1 genotypes Table 2 represents genotype frequency of GSTM1 and GSTT1 gene in different study groups. GSTM1 null genotype showed significance between study subjects. On the other hand, GSTT1 null genotype showed no significance. The analysis of GSTM1 and GSTT1 genotype in pre-eclampsia patients and control subjects and estimated risk is presented in Table 3 . For GSTT1 gene, the difference in the genotype categories (present and null) among study subjects was not significant. But GSTM1 null genotype showed significance between study groups (P < 0.001) ( Table 3 ). In case of GSTT1 and GSTM1 combined genotypes, null genotype for both GSTT1 and GSTM1 gene showed significant difference when compared to GSTT1 and GSTM1 present genotype (P < 0.001).
The risk for pre-eclampsia was also calculated in relation to the GSTT1 and GSTM1 (present and null) genotypes. In case of GSTT1 gene, patients having null genotype are at higher risk of developing preeclampsia when compared to control subjects (OR = 1.22; 95% CI = 0.58-2.57; P = 0.101) although not statistically significant. For GSTM1 gene, the difference in the genotype categories (present and null) among study subjects was statistically significant (P < 0.001) and risk of developing the disease also higher in case of null genotype when compared to control subjects (OR = 4.75; 95% CI = 2.17-10.39; P < 0.001) ( Table 3 ). In case of GSTT1 and GSTM1 combined genotype, patients having both null genotypes for GSTT1 and GSTM1 gene showed significant (P < 0.001) higher risk of developing pre-eclampsia when compared to control subjects (OR = 7.64; 95% CI = 2.38-24.60; P < 0.001) ( Table 3 ). In addition, patients having at least one present genotype for either GSTT1 or GSTM1 gene showed higher risk for pre-eclampsia compared to control group (OR = 1.21; 95% CI = 0.56-2.62; P = 0.067) but not statistically significant.
Genotypic distribution of serum parameters in pre-eclampsia patients t-Test was used to analyze different serum parameter level for different genotypes in pre-eclampsia patients (Table 4) . SGPT and fibrin degradation product (FDP) showed significance between two genotypic groups (P < 0.05). Other parameters, such as hemoglobin, creatinine, uric acid and RBS showed no significance between two genotypic groups.
Discussion
In our study, there was no association between GSTT1 null genotype with pre-eclampsia. Study conducted by Guan et al. 19 found significant correlation between GSTT1 null genotype with the development of preeclampsia in Chinese population. But they found GSTM1 null genotype as protective genotype for developing pre-eclampsia, which is opposite to our study. Furthermore, combined null genotype for GSTT1 and M1 gene showed even lower risk of pre-eclampsia, which is also opposite to our study. Study conducted in Iranian population showed no significance between GSTT1 and GSTM1 null genotype with the risk of preeclampsia. 21 According to the study of Matos et al.,
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GSTT1 null genotype is associated with the risk of pre-eclampsia, which is also opposite to the result of our study. They also found no association between GSTM1 gene polymorphism and pre-eclampsia. Study conducted by Sandoval-Carrillo et al. 20 found a significant relation with GSTT1 null genotype and the risk of pre-eclampsia in Mexican mestizo population. They also observed that combined null genotype for GSTT1 and M1 gene further increases the risk of pre-eclampsia, which is similar to our study. Another study on Turkish population found no association between GSTT1 and GSTM1 gene polymorphism and the risk of developing pre-eclampsia. 18 Baseline characteristics, such as age, RBS, uric acid and creatinine, showed no significance between patients and controls. SGPT level is significantly higher in patients compare to healthy subject (P < 0.01). Study conducted by Dacaj et al. 8 showed higher level of SGPT in pre-eclamptic women similar to our study. Hemoglobin level is higher in control group when we compare it with the patient group (P < 0.001). A study showed that maternal z score of hemoglobin was significantly higher in pre-eclampsia patients compared to controls. 26 t-Test was used to analyze genotypic distribution of different serum parameters in pre-eclampsia patients, which is enlisted in Table 4 . SGPT and FDP showed significance between two genotypic groups (P < 0.05). In our study, we found significant higher level of SGPT in GSTM1 present genotypic group compared to null genotypic group. Also, FDP level was significantly higher in GSTM1 present genotype compared to GSTM1 null genotype. This result seems contradictory because we found higher level of SGPT and FDP level in present genotype. This may because of the lack of relationship between these parameters with the genotype of GST genes. As pre-eclampsia is a multifactorial disease, there are other factors, which may influence these parameters. Other parameters, such as hemoglobin, creatinine, uric acid and RBS, showed no significance between two genotypic groups. On the basis of our study, GSTM1 alone and GSTM1 and T1 in combination increases the risk of pre-eclampsia. The study has many physical data and we tried to adjust the OD according to our data. Therefore, the OD has better accuracy relative to raw OD of the polymorphic data. Finally, the sample size could be increased to improve the strength of polymorphism-associated statements.
